| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRCLINONC.2013.144 |
| P698 | PubMed publication ID | 23939548 |
| P50 | author | David H. Gutmann | Q56670301 |
| P2093 | author name string | Andrew L Lin | |
| P2860 | cites work | Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients | Q24294421 |
| Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 | Q24313491 | ||
| The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins | Q24324729 | ||
| A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity | Q24514960 | ||
| Malignant peripheral nerve sheath tumours in neurofibromatosis 1 | Q24679356 | ||
| Mouse models of neurofibromatosis 1 and 2. | Q24682869 | ||
| Germline mutation of INI1/SMARCB1 in familial schwannomatosis | Q24682982 | ||
| NF1 gene and neurofibromatosis 1 | Q28142087 | ||
| Plexiform neurofibromas in NF1: toward biologic-based therapy | Q28202004 | ||
| RAS oncogenes: weaving a tumorigenic web | Q28250360 | ||
| Diagnostic criteria for schwannomatosis | Q28256490 | ||
| The neurofibromatosis type 1 gene encodes a protein related to GAP | Q28301160 | ||
| Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging | Q28305337 | ||
| Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. | Q28507503 | ||
| Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder | Q28508406 | ||
| Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes | Q28510368 | ||
| Mouse models of tumor development in neurofibromatosis type 1 | Q28591083 | ||
| Mouse tumor model for neurofibromatosis type 1 | Q28591456 | ||
| Neurofibromin regulates G protein-stimulated adenylyl cyclase activity | Q28594248 | ||
| The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 | Q28609120 | ||
| Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells | Q28728224 | ||
| Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis | Q28730289 | ||
| Neurofibromatosis type 2. | Q30391375 | ||
| Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. | Q30406342 | ||
| Optimizing biologically targeted clinical trials for neurofibromatosis. | Q30438898 | ||
| Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. | Q30450038 | ||
| ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma | Q30474678 | ||
| Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety | Q72064470 | ||
| Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity | Q72230873 | ||
| Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1 | Q73182784 | ||
| Characterization of Pheochromocytomas in a Mouse Strain with a Targeted Disruptive Mutation of the Neurofibromatosis Gene Nf1 | Q74454260 | ||
| Neurofibromatosis 2 and malignant mesothelioma | Q74506353 | ||
| Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausen's disease | Q77794222 | ||
| Phase II trial of pirfenidone in adults with neurofibromatosis type 1 | Q79226152 | ||
| Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas | Q80350602 | ||
| Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1 | Q80665535 | ||
| The neurofibromatoses | Q83821184 | ||
| Early Outcomes for Malignant Peripheral Nerve Sheath Tumor Treated With Chemotherapy | Q85024795 | ||
| Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein | Q30500623 | ||
| Brainstem lesions in neurofibromatosis type 1. | Q31135561 | ||
| Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin | Q33403043 | ||
| Intracranial gliomas in neurofibromatosis type 1. | Q33723870 | ||
| von Recklinghausen's disease and pheochromocytomas | Q33753382 | ||
| Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells | Q33757962 | ||
| Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity | Q33831164 | ||
| Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. | Q34020644 | ||
| Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. | Q34131794 | ||
| Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients | Q34288675 | ||
| Neurofibromatosis type 1 and childhood cancer | Q34357450 | ||
| Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought | Q34392256 | ||
| Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. | Q34441257 | ||
| The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis | Q34474913 | ||
| Neurofibromas in NF1: Schwann cell origin and role of tumor environment | Q34509108 | ||
| Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma | Q34509145 | ||
| Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas | Q34555308 | ||
| The development of cutaneous neurofibromas | Q34760769 | ||
| Neurofibromas in children with neurofibromatosis 1. | Q34982044 | ||
| A clinical study of type 1 neurofibromatosis in north west England | Q35431845 | ||
| Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse | Q35776239 | ||
| Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study | Q36080152 | ||
| Contact-dependent inhibition of EGFR signaling by Nf2/Merlin | Q36118464 | ||
| Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. | Q36157726 | ||
| Management of the patient and family with neurofibromatosis 2: a consensus conference statement | Q36251326 | ||
| Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation | Q36298172 | ||
| MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. | Q36497139 | ||
| CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors | Q36675171 | ||
| The management of brainstem gliomas in patients with neurofibromatosis 1. | Q36801096 | ||
| All in the family: using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors | Q36920227 | ||
| Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening | Q37004572 | ||
| Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours | Q37152087 | ||
| NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth | Q37275182 | ||
| Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation | Q37383632 | ||
| Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. | Q51891133 | ||
| Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. | Q53116195 | ||
| Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. | Q53359692 | ||
| Merlin and ERM proteins: unappreciated roles in cancer development? | Q53372846 | ||
| Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. | Q53887835 | ||
| Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. | Q55462234 | ||
| Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. | Q55463441 | ||
| Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. | Q55470115 | ||
| Cerebellar gliomas in children with NF1: pathology and surgery. | Q55475254 | ||
| Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. | Q55478770 | ||
| Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. | Q55481914 | ||
| Neurofibromatosis type 1 | Q56093335 | ||
| Life expectancy in hereditary cancer predisposing diseases: an observational study | Q57266560 | ||
| Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service | Q57266646 | ||
| An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2) | Q57266659 | ||
| Neurofibromatosis 2 (NF2) and Malignant Mesothelioma in a Man with a Constitutional NF2 Missense Mutation | Q57266756 | ||
| Evaluation of clinical diagnostic criteria for neurofibromatosis 2 | Q57266780 | ||
| National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel | Q57266948 | ||
| A clinical study of type 2 neurofibromatosis | Q57266958 | ||
| What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers | Q57657390 | ||
| Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1 | Q60696729 | ||
| Optic gliomas in children with neurofibromatosis type 1 | Q69195503 | ||
| Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference | Q70384871 | ||
| Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases | Q70579625 | ||
| Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity | Q71525420 | ||
| Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells | Q71594074 | ||
| Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I | Q71639478 | ||
| Pten haploinsufficiency accelerates formation of high-grade astrocytomas | Q37384874 | ||
| Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. | Q37737382 | ||
| PET/CT in primary musculoskeletal tumours: a step forward | Q37767627 | ||
| [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation | Q37992516 | ||
| Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. | Q38075109 | ||
| Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. | Q39555847 | ||
| Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases | Q39587986 | ||
| A conditional mouse model for malignant mesothelioma | Q40004544 | ||
| TORC1 is essential for NF1-associated malignancies | Q40029605 | ||
| Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history | Q40368124 | ||
| Schwannoma (neurilemoma) with malignant transformation. A rare, distinctive peripheral nerve tumor | Q40692942 | ||
| Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. | Q41909163 | ||
| Precocious puberty in children with neurofibromatosis type 1. | Q42489641 | ||
| Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1 | Q42729073 | ||
| Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis | Q42806305 | ||
| The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. | Q42823880 | ||
| Universal absence of merlin, but not other ERM family members, in schwannomas. | Q42839207 | ||
| Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. | Q43238316 | ||
| Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). | Q43707439 | ||
| Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. | Q44276749 | ||
| The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes | Q44605310 | ||
| Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders | Q46134351 | ||
| Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors | Q46417560 | ||
| Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells | Q46486969 | ||
| Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. | Q46721093 | ||
| Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas | Q46900234 | ||
| [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study | Q46954213 | ||
| Novel and recurrent mutations in the NF1 gene in Italian patients with neurofibromatosis type 1. | Q47596589 | ||
| Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. | Q48106714 | ||
| A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor | Q48129277 | ||
| Neurofibromatosis 2 in the pediatric age group | Q48256105 | ||
| von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata | Q48639747 | ||
| Radiosurgery for type II neurofibromatosis. | Q50449685 | ||
| Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods. | Q50493209 | ||
| The neuroimaging and clinical spectrum of neurofibromatosis 2. | Q50514920 | ||
| Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. | Q50931387 | ||
| Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I. | Q50994646 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 616-624 | |
| P577 | publication date | 2013-08-13 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Advances in the treatment of neurofibromatosis-associated tumours | |
| P478 | volume | 10 |
| Q38635798 | A 3D-Engineered Conformal Implant Releases DNA Nanocomplexs for Eradicating the Postsurgery Residual Glioblastoma |
| Q27334571 | A critical role for NF2 and the Hippo pathway in branching morphogenesis |
| Q38713914 | CNS Tumors in Neurofibromatosis. |
| Q98771173 | Computed Tomography-Based Differentiation of Benign and Malignant Craniofacial Lesions in Neurofibromatosis Type I Patients: A Machine Learning Approach |
| Q52836750 | Deguelins, Natural Product Modulators of NF1-Defective Astrocytoma Cell Growth Identified by High-Throughput Screening of Partially Purified Natural Product Extracts. |
| Q89184709 | Demographic, Clinical and Histopathological Features of Oral Neural Neoplasms: A Retrospective Study |
| Q53143431 | Diagnosis and Management of Hereditary Carcinoids. |
| Q51721478 | Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma. |
| Q57298266 | Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 |
| Q29616044 | Genome-scale CRISPR-Cas9 knockout screening in human cells |
| Q38746881 | Immortalization of human normal and NF1 neurofibroma Schwann cells |
| Q38815400 | Is there a role for early chemotherapy in the management of pituitary adenomas? |
| Q52425277 | Malignant Peripheral Nerve Sheath Tumors. |
| Q57798425 | Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial |
| Q47197942 | Modification of pedicle lengthening through perforator transposition in free anterolateral thigh flaps with pedicle size discrepancy: A case report. |
| Q39174603 | Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma |
| Q53514814 | Neurodevelopment. "RASopathic" astrocytes constrain neural plasticity. |
| Q34412515 | Neurofibromatoses: part 1 - diagnosis and differential diagnosis. |
| Q89348728 | Neurofibromatosis type 1 |
| Q54940448 | Neurofibromatosis type I and multiple myeloma coexistence: A possible link? |
| Q53464959 | Neurofibromatosis: part 2--clinical management. |
| Q40465319 | Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors. |
| Q58699185 | Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas |
| Q57801671 | Spatiotemporal loss of NF1 in Schwann cell lineage leads to different types of cutaneous neurofibroma susceptible to modification by the Hippo pathway |
| Q90160827 | Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1 |
| Q42340618 | Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients. |
| Q38151546 | The impact of germline mutations on targeted therapy |
| Q37641630 | The role of nerve microenvironment for neurofibroma development |
| Q36787769 | Triterpenoid saponin flaccidoside II from Anemone flaccida triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors via the MAPK-HO-1 pathway |
Search more.